EssilorLuxottica revenue tops €7.4bn as eyewear and retail growth beat Q3 expectations

EssilorLuxottica reported stronger-than-expected third-quarter revenue as growth across eyewear, optical retail and vision-care products helped the Ray-Ban and Oakley owner produce another quarter of broad-based expansion. Revenue reached €7.49 billion, up 9% from a year earlier on a reported basis and 7.2% at constant exchange rates, ahead of the roughly €7.36 billion expected by analysts. Direct-to-consumer sales increased 10.6% at constant currencies, supported by comparable-store growth of 6.8%, while every major geographic region contributed to the expansion. The results reinforce that EssilorLuxottica’s growth story remains supported by its much larger traditional eyewear and eyecare operations even as investor attention increasingly focuses on newer products such as connected glasses.

The quarter takes EssilorLuxottica’s revenue for the first nine months of 2026 to €22.30 billion, an increase of 6.8% on a reported basis and 8.9% at constant exchange rates. Management said its eyecare, eyewear and medical-technology businesses grew more than 6% during both the third quarter and the first nine months, while the company’s myopia-management portfolio expanded 24%. Wearables grew 20%, but that represented a sharp slowdown from the near-doubling reported during the second quarter, shifting attention back toward the durability of EssilorLuxottica’s underlying optical franchise.

Direct-to-consumer growth shows EssilorLuxottica’s retail network remains a major earnings engine

EssilorLuxottica’s direct-to-consumer business was one of the strongest areas of the quarter, increasing 10.6% at constant exchange rates while comparable-store sales rose 6.8%. That performance matters because the company controls a large global retail network alongside its manufacturing and wholesale operations, allowing it to capture economics from both producing eyewear and selling products directly to consumers. The portfolio includes major optical and sunglass retail banners alongside globally recognized brands such as Ray-Ban and Oakley.

The retail momentum extends the pattern established during the first half, when second-quarter comparable-store sales increased 8%. Direct consumer relationships can become especially valuable when shoppers purchase prescription lenses, frames, sunglasses and other vision products together, helping EssilorLuxottica capture more revenue from each customer while controlling merchandising and pricing. The model also provides the company with a distribution network for introducing new products without depending entirely on independent retailers.

Professional Solutions, which supplies optical professionals and other business customers, grew at a slower 3.4% constant-currency rate during the third quarter. Management noted that the comparison was demanding because the business had generated double-digit growth during the prior-year period. The difference between the two channels means direct-to-consumer operations were the stronger contributor to the latest acceleration, although Professional Solutions remains an important part of the vertically integrated business model.

Regional performance was also broad rather than concentrated in one market. North America, EssilorLuxottica’s largest geographic region, increased revenue 4.7% at constant currencies, while Asia-Pacific delivered double-digit growth. Management specifically highlighted strong European direct-to-consumer performance and continued expansion across Asia, where rising demand for premium optical products and myopia-management solutions has become increasingly important.

That geographic balance reduces reliance on any single consumer market. Economic weakness or slower discretionary spending in one region can still affect sunglasses and premium frames, but prescription lenses and vision correction carry a more defensive demand profile than many other consumer categories. EssilorLuxottica’s combination of medical necessity, fashion and retail exposure remains one of the characteristics separating it from conventional luxury or apparel businesses.

Myopia management grows 24% as healthcare products broaden the company beyond traditional eyewear

One of the clearest structural growth areas remains myopia management. Revenue from the portfolio increased 24% during the third quarter and by the same percentage across the first nine months of 2026, continuing a multiyear expansion driven by products designed to slow the progression of myopia in children.

The category gives EssilorLuxottica exposure to a healthcare need rather than simply replacement eyewear. Myopia has become increasingly common globally, particularly in parts of Asia, creating demand for specialized lenses and clinical solutions intended to manage progression at younger ages. The company’s Stellest lens has become one of its flagship products in the category and has continued expanding geographically.

The healthcare orientation is strategically useful because it broadens EssilorLuxottica beyond the conventional frame-and-lens cycle. Consumers may postpone replacing fashion sunglasses or premium frames when economic conditions weaken, but clinical vision-management products can have different demand characteristics. That creates another potential source of recurring growth as EssilorLuxottica expands relationships with optometrists, ophthalmologists and families.

Management also continues positioning medical technology as a larger part of the company’s long-term identity. Eyecare, eyewear and medtech collectively grew by more than 6% in both the quarter and year-to-date period. The strategy increasingly places EssilorLuxottica at the intersection of consumer products and medical vision care rather than treating it solely as the owner of major eyewear brands.

That broader positioning was already visible in first-half profitability. Adjusted operating profit increased 15% during the first six months of 2026, while adjusted operating margin reached 18.6% and 18.9% at constant exchange rates. Free cash flow totaled approximately €1.07 billion, more than €100 million above the comparable 2025 period. Those numbers show that revenue expansion has been accompanied by improving profitability rather than requiring disproportionate spending to generate growth.

The combination of strong cash generation and expanding healthcare categories is particularly relevant for long-term valuation. EssilorLuxottica already operates at enormous scale, so maintaining high-single-digit organic growth becomes progressively harder as the revenue base expands. Categories such as myopia management give the company an opportunity to add growth without relying entirely on opening more optical stores or raising prices on established eyewear products.

Wearables reach €486 million in Q3 revenue but growth slows sharply from the second quarter

Wearables remain important, but the latest numbers provide a more measured picture than the extraordinary growth rates reported earlier in the year. EssilorLuxottica disclosed for the first time that wearables generated €486 million of third-quarter revenue, representing approximately 6.5% of total group sales. Revenue in the category increased 20% year over year, compared with growth of almost 100% during the second quarter.

The slower rate partly reflects much more difficult comparisons after the category expanded rapidly during 2025. It also demonstrates why the wider EssilorLuxottica business remains important to the investment case. Even after substantial growth, wearables still account for a relatively small percentage of total group revenue, while traditional eyecare, eyewear and medtech remain the primary financial engine.

That distinction matters because EssilorLuxottica’s share price has become increasingly sensitive to expectations surrounding connected glasses. Investors have assigned substantial strategic value to the company’s early position in the category, making any slowdown capable of influencing sentiment even when total group revenue continues beating expectations. Reuters noted that the shares have fallen roughly by half from their highs over the past year amid concerns around competition, privacy issues and questions about how profitable connected eyewear ultimately becomes.

Management nevertheless remains positive on the category going into the holiday period, while Nuance Audio provides another wearable application through hearing-support technology integrated into glasses. The company launched Nuance Audio Plus in September and expects its expanding wearable portfolio to contribute to fourth-quarter demand.

For investors, the important point is that EssilorLuxottica does not need wearable revenue to double every quarter for the company to grow. A 20% expansion remains strong in absolute terms, and the underlying optical business continues advancing at a mid-to-high-single-digit pace. The risk emerges primarily when the market valuation assumes dramatically faster adoption than the category ultimately delivers.

EssilorLuxottica shares remain well below their highs despite the Q3 revenue beat

EssilorLuxottica shares were trading around €150.50 on October 20, little changed to modestly lower after the third-quarter release. The company’s market capitalization stands near €70 billion, while the stock remains dramatically below its 52-week high of approximately €323.80 and only modestly above the 52-week low of €138.30.

That decline has materially changed the valuation debate. EssilorLuxottica now trades at roughly 28 times trailing earnings based on recent market data, still a premium multiple but considerably less demanding than valuations implied when the shares were trading above €300. The company also pays an annual dividend of approximately €4 per share, producing a yield near 2.6% at current levels.

Wall Street sentiment remains broadly constructive despite recent target reductions. Twenty-three analysts tracked by MarketScreener carry an average price target near €220, with the overall consensus at Outperform. Bank of America recently reduced its target from €237 to €205 while retaining a Buy view, illustrating that analysts have lowered expectations without abandoning the longer-term growth thesis.

The third-quarter revenue beat gives those investors another data point supporting the core business. Revenue exceeded consensus by approximately €126 million, direct-to-consumer growth remained double digit and all regions contributed. More importantly, the company achieved those results even as the wearable growth rate moderated substantially.

That makes the current investment debate more balanced than it was when expectations centered heavily on one rapidly growing product category. EssilorLuxottica still carries risks around valuation, consumer spending, foreign exchange, competition and regulatory scrutiny of connected glasses. Yet the quarter demonstrates that the company continues generating meaningful growth from optical retail, prescription lenses, healthcare products and established eyewear brands independently of those newer businesses.

The next test will be whether fourth-quarter holiday demand can maintain the direct-to-consumer momentum and whether the company can preserve first-half margin gains as its product mix evolves. If traditional eyewear continues growing above 6% while myopia management remains in the 20%-plus range, EssilorLuxottica may not need extraordinary wearable growth to support a premium valuation. If those core categories slow alongside wearables, the recent share-price reset could prove more justified.

Key takeaways on EssilorLuxottica’s Q3 revenue and what investors should watch

• EssilorLuxottica generated €7.49 billion of third-quarter revenue, up 9% reported and 7.2% at constant exchange rates.
• Revenue exceeded the roughly €7.36 billion analyst consensus, giving the company a clear top-line beat.
• Direct-to-consumer revenue increased 10.6% while comparable-store sales rose 6.8%, making retail one of the quarter’s strongest growth drivers.
• Traditional eyecare, eyewear and medtech revenue grew more than 6% in both Q3 and the first nine months of 2026.
• The myopia-management portfolio expanded 24%, reinforcing its role as one of EssilorLuxottica’s strongest healthcare growth categories.
• Wearables produced €486 million of Q3 revenue and grew 20%, although that was substantially slower than the near-100% growth reported in Q2.
• First-half adjusted operating margin reached 18.6% and free cash flow totaled approximately €1.07 billion.
• EssilorLuxottica shares remain around €150, far below their 52-week high, despite analysts maintaining an average target near €220.
• Investors should watch holiday retail demand, margin performance and whether core optical growth can remain strong as wearable comparisons become more difficult.